News
-
-
PRESS RELEASE
BioNxt Secures Unitary European Patent for Sublingual Cladribine ODF Platform Across 18 Countries
BioNxt Solutions Inc. secures Unitary Patent registration for sublingual cladribine oral thin film technology in Europe, enhancing commercialization prospects and partnership opportunities -
-
PRESS RELEASE
BioNxt Advances Semaglutide as First Application of Broad GLP-1 ODF Platform Strategy
BioNxt Solutions Inc. provides update on semaglutide ODF program and platform strategy. Focus on GLP-1 receptor agonists and peptide-based therapeutics. Potential market growth and commercial outlook discussed -
-
PRESS RELEASE
BioNxt Enters Commercialization Phase with Global Patent Protection and U.S. Fast Track Strategy for Sublingual Drug Delivery Platform
BioNxt Solutions Inc. announces major advancement in commercialization strategy with global patent portfolio expansion for sublingual drug delivery platform. Strong intellectual property and transitioning to commercialization phase -
-
PRESS RELEASE
BioNxt Signs Strategic Agreement for Eurasian Commercialization Following Cladribine ODF Patent Grant in Eurasia and Europe
BioNxt Solutions Inc. signs LOI for commercialization of sublingual cladribine ODF in Eurasian Patent Organization member states, strengthening global IP position and pursuing licensing opportunities -
-
PRESS RELEASE
BioNxt Announces Closing of Shares for Debt Settlement
BioNxt Solutions Inc. settles $2.7M debt with 6,008,883 common shares. Compensation shares issued to Canaccord Genuity Corp. for facilitating the debt settlement. Company focuses on drug delivery tech and pharmaceutical development
